HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes

Area of Science:

• Endocrinology
• Metabolic Diseases
• Cell Biology

Background:

• Type 2 diabetes progression involves sustained metabolic overload of pancreatic beta cells.
• This overload may induce a hypoxic cellular phenotype mediated by hypoxia-inducible factor-1α (HIF-1α).

Purpose of the Study:

• To investigate the role of HIF-1α in diabetic beta cell dysfunction.
• To evaluate the therapeutic potential of the HIF-1α inhibitor PX-478 in preserving beta cell function and improving glycemic control.

Main Methods:

• Detection of HIF-1α protein in pancreatic beta cells of diabetic mouse models.
• Assessment of beta cell function in mouse islets and db/db mice treated with PX-478.
• Evaluation of glucose homeostasis and insulin levels in diabetic mice treated with PX-478.
• Analysis of gene expression, insulin content, and granule formation in treated islets.
• Testing PX-478 efficacy in human islet organoids under high glucose conditions.

Main Results:

• HIF-1α protein was found in beta cells of diabetic mice.
• PX-478 treatment improved beta cell function, suppressing abnormal insulin release and restoring Ca2+ oscillations.
• PX-478 treatment in db/db mice prevented hyperglycemia and diabetes progression by maintaining insulin levels.
• PX-478 improved glucose homeostasis recovery in streptozotocin-induced diabetic mice.
• Treated islets showed increased insulin content, enhanced expression of beta cell function genes, and reduced dedifferentiation markers.
• Human islet organoids demonstrated improved glucose-stimulated insulin secretion after PX-478 treatment.

Conclusions:

• HIF-1α plays a significant role in mediating beta cell dysfunction under metabolic stress.
• PX-478 effectively preserves beta cell function and improves glycemic control in preclinical models of type 2 diabetes.
• PX-478 demonstrates potential as a novel therapeutic agent for type 2 diabetes by targeting HIF-1α.